Uncovering the differential impact of ESR1 and PIK3CA codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS).

被引：2

作者：

Gerratana, Lorenzo

Davis, Andrew A.

Velimirovic, Marko

D'Amico, Paolo

Shah, Ami N.

Clifton, Katherine

Zhang, Qiang

Dai, Charles Sichao

Reduzzi, Carolina

Hensing, Whitney L.

Bonotto, Marta

Mazzeo, Roberta

Wehbe, Firas Hazem

Franzoni, Alessandra

Belletti, Barbara

Behdad, Amir

Ma, Cynthia X.

Puglisi, Fabio

Bardia, Aditya

Cristofanilli, Massimo

机构：

[1] Northwestern Univ, Feinberg Sch Med, Dept Med Hematol & Oncol, Chicago, IL 60611 USA

[2] Univ Udine, Dept Med DAME, Chicago, IL USA

[3] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[4] Harvard Med Sch, Boston, MA 02115 USA

[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[6] Northwestern Univ, Chicago, IL 60611 USA

[7] Washington Univ, Sch Med, St Louis, MO 63110 USA

[8] Northwestern Univ, Lurie Canc Ctr, Div Hematol Oncol, Dept Med, Chicago, IL 60611 USA

[9] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA

[10] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[11] Univ Hosp Udine, Dept Oncol, Udine, Italy

[12] Univ Udine, Dept Med Area, Udine, Italy

[13] CRO Aviano, IRCCS, Dept Med Oncol, Udine, Italy

[14] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[15] Azienda Sanitaria Univ Friuli Cent ASUFC, Inst Human Genet, Udine, Italy

[16] IRCCS, Ctr Riferimento Oncol Aviano CRO, Unit Mol Oncol, Aviano, Italy

[17] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA

[18] Univ Udine, Dept Med DAME, Udine, Italy

[19] IRCCS, Ctr Riferimento Oncol Aviano CRO, Dipartimento Oncol Med, Udine, Italy

[20] Harvard Med, Massachusetts Gen Hosp, Boston, MA USA

[21] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.1033

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1033

引用

页数：3

共 39 条

[31] Comparison of next-generation sequencing and real-time PCR for PIK3CA testing in hormone receptor-positive/HER2-negative breast cancer on metastatic and matched primary tumor samples
Venetis, Konstantinos
Pepe, Francesco
Sajjadi, Elham
Bonizzi, Giuseppina
Ivanova, Mariia
Vacirca, Davide
Rappa, Alessandra
Barberis, Massimo
Viale, Giuseppe
Guerini-Rocco, Elena
Munzone, Elisabetta
Malapelle, Umberto
Fusco, Nicola
CANCER RESEARCH, 2023, 83 (05)
[32] Genomic alterations (GA) in ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) patients (pts) with metastatic breast cancer (MBC): Co-occurrence and prevalence along treatment course
Bhave, Manali A.
Quintanilha, Julia
Ross, Jeffrey S.
Graf, Ryon P.
Levy, Mia Alyce
Kalinsky, Kevin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[33] Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
Takashi Takeshita
Yutaka Yamamoto
Mutsuko Yamamoto-Ibusuki
Mai Tomiguchi
Aiko Sueta
Keiichi Murakami
Hirotaka Iwase
Molecular Cancer, 17
[34] Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
Takeshita, Takashi
Yamamoto, Yutaka
Yamamoto-Ibusuki, Mutsuko
Tomiguchi, Mai
Sueta, Aiko
Murakami, Keiichi
Iwase, Hirotaka
MOLECULAR CANCER, 2018, 17
[35] Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2-Breast Cancer
Venetis, Konstantinos
Pepe, Francesco
Munzone, Elisabetta
Sajjadi, Elham
Russo, Gianluca
Pisapia, Pasquale
Ivanova, Mariia
Bonizzi, Giuseppina
Vacirca, Davide
Rappa, Alessandra
Ranghiero, Alberto
Taormina, Sergio Vincenzo
Viale, Giuseppe
Troncone, Giancarlo
Barberis, Massimo
Guerini-Rocco, Elena
Malapelle, Umberto
Fusco, Nicola
CELLS, 2022, 11 (22)
[36] Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA
Dickler, M. N.
Saura, C.
Oliveira, M.
Richards, D. A.
Krop, I. E.
Cervantes, A.
Stout, T. J.
Jin, H.
Savage, H. M.
Wilson, T. R.
Baselga, J.
CANCER RESEARCH, 2017, 77
[37] Treatment of ESR1 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo
Young, A.
Crocker, L.
Cheng, E.
Lacap, J.
Hamilton, P.
Oeh, J.
Ingalla, E.
Arrazate, A.
Hager, J.
Nannini, M.
Friedman, L.
Daemen, A.
Giltnane, J.
Sampath, D.
CANCER RESEARCH, 2017, 77
[38] Clinical outcomes of alpelisib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer with PIK3CA alterations detected in plasma ctDNA by next-generation sequencing: Biomarker analysis from the SOLAR-1 study
Ciruelos, Eva M.
Loibl, Sibylle
Mayer, Ingrid A.
Campone, Mario
Rugo, Hope S.
Arnedos, Monica
Iwata, Hiroji
Conte, Pier Franco
Andre, Fabrice
Reising, Albert
Ma, Chong
Miller, Michelle
Babbar, Naveen
Juric, Dejan
CANCER RESEARCH, 2021, 81 (04)
[39] Clinical outcomes of alpelisib in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer by next-generation sequencing-detected PIK3CA alteration status and phosphatase and tensin homolog loss: Biomarker analysis from the SOLAR-1 study
Juric, Dejan
Andre, Fabrice
Singer, Christian F.
Sohn, Joohyuk
Campone, Mario
Loibl, Sibylle
Conte, Pierfranco
Iwata, Hiroji
Ciruelos, Eva
Mayer, Ingri D. A.
Reising, Albert
Ma, Chong
Miller, Michelle
Babbar, Naveen
Rugo, Hope S.
CANCER RESEARCH, 2020, 80 (04)

← 1 2 3 4 →